Announcements Trials
Browse Landscape

Phase

Phase 3 4

Status

Completed 3Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Genitourinary 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 3Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 37Carboplatin 31Cisplatin 30Paclitaxel 23Nivolumab 21Pemetrexed 21Dexamethasone 18Gemcitabine 18Ipilimumab 15Docetaxel 13Fluorouracil 13Capecitabine 12Rituximab 12Cyclophosphamide 10Cytarabine 10Trastuzumab 9atezolizumab 9daratumumab 9olaparib 9130-nm albumin-bound paclitaxel 8Lenalidomide 8Prednisone 8durvalumab 8trastuzumab deruxtecan 8Bevacizumab 7Bortezomib 7Fulvestrant 7Oxaliplatin 7Vinorelbine 7cabozantinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × Has announcements × Saline Solution × Clear all
NCT03142334 2026-03-10

KEYNOTE-564

Merck Sharp & Dohme LLC

Phase 3 Completed
994 enrolled 10 charts 1 FDA
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT05116189 2026-03-09

KEYNOTE-B96

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
643 enrolled 17 charts 1 FDA
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03635567 2026-02-04

KEYNOTE-826

Merck Sharp & Dohme LLC

Phase 3 Completed
617 enrolled 29 charts 1 FDA
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT02578680 2024-09-20

MK-3475-189

Merck Sharp & Dohme LLC

Phase 3 Completed
616 enrolled 19 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡